A1BG-AS1 promotes the biological functions of osteosarcoma cells via regulating the microRNA-148a-3p/USP22 axis and stabilizing the expression of SIRT1 through deubiquitinase function

References

• Chen C, Xie L, Ren T, et al. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021 Mar 1;500:1–10. doi: 10.1016/j.canlet.2020.12.024
   PubMed Web of Science ®Google Scholar
• Krishnamurthy K, Alghamdi S, Kochiyil J, et al. Osteosarcoma presenting with malignant pleural effusion in a 55 year old. Respir Med Case Rep. 2018;25:314–317. doi: 10.1016/j.rmcr.2018.10.017
   PubMed Web of Science ®Google Scholar
• Cersosimo F, Lonardi S, Bernardini G, et al. Tumor-associated macrophages in osteosarcoma: from mechanisms to therapy. Int J Mol Sci. 2020 Jul 23;21(15):5207. doi: 10.3390/ijms21155207
   PubMed Web of Science ®Google Scholar
• Simpson E, Brown HL. Understanding osteosarcomas. JAAPA. 2018 Aug;31(8):15–19. doi: 10.1097/01.JAA.0000541477.24116.8d
   PubMedGoogle Scholar
• Kager L, Tamamyan G, Bielack S. Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncol. 2017 Feb;13(4):357–368. doi: 10.2217/fon-2016-0261
   PubMed Web of Science ®Google Scholar
• Jarroux J, Morillon A, Pinskaya M. History, discovery, and classification of lncRnas. Adv Exp Med Biol. 2017;1008:1–46.
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Shirvani-Farsani Z, Hussen BM, et al. The critical roles of lncRnas in the development of osteosarcoma. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2021 Mar;135:111217.
   PubMed Web of Science ®Google Scholar
• Cai S, Zhou Y, Pan Y, et al. Long non-coding RNA A1BG-AS1 promotes tumorigenesis in breast cancer by sponging microRNA-485-5p and consequently increasing expression of FLOT1 expression. Hum Cell. 2021 Sep;34(5):1517–1531. doi: 10.1007/s13577-021-00554-8
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017 Mar;16(3):203–222. doi: 10.1038/nrd.2016.246
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Chalk AM, Ng AJ, et al. Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death. Oncogene. 2016 Oct 6;35(40):5282–5294. doi: 10.1038/onc.2016.68
   PubMed Web of Science ®Google Scholar
• Yang H, Peng Z, Da Z, et al. MicroRNA-148a acts as a tumor suppressor in osteosarcoma via targeting rho-associated coiled-coil kinase. Oncol Res. 2017 Sep 21;25(8):1231–1243. doi: 10.3727/096504017X14850134190255
   PubMed Web of Science ®Google Scholar
• Zhao J, Cheng L. Long non-coding RNA CCAT1/miR-148a axis promotes osteosarcoma proliferation and migration through regulating PIK3IP1. Acta Biochim Biophys Sin. 2017 Jun 1;49(6):503–512. doi: 10.1093/abbs/gmx041
   Google Scholar
• Melo-Cardenas J, Zhang Y, Zhang DD, et al. Ubiquitin-specific peptidase 22 functions and its involvement in disease. Oncotarget. 2016 Jul 12;7(28):44848–44856. doi: 10.18632/oncotarget.8602
   PubMedGoogle Scholar
• Zhang D, Jiang F, Wang X, et al. Downregulation of ubiquitin-specific protease 22 inhibits proliferation, invasion, and epithelial-mesenchymal transition in osteosarcoma cells. Oncol Res. 2017 May 24;25(5):743–751. doi: 10.3727/096504016X14772395226335
   PubMed Web of Science ®Google Scholar
• Lin Z, Yang H, Kong Q, et al. USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Molecular Cell. 2012 May 25;46(4):484–494. doi: 10.1016/j.molcel.2012.03.024
   PubMed Web of Science ®Google Scholar
• Zhao B, Li X, Zhou L, et al. SIRT1: a potential tumour biomarker and therapeutic target. J Drug Targeting. 2019 Dec;27(10):1046–1052. doi: 10.1080/1061186X.2019.1605519
   PubMed Web of Science ®Google Scholar
• Liu W, Wang D, Liu L, et al. miR-140 inhibits osteosarcoma progression by impairing USP22-mediated LSD1 stabilization and promoting p21 expression. Mol Ther Nucleic Acids. 2021 Jun 4;24:436–448. doi: 10.1016/j.omtn.2021.01.029
   PubMedGoogle Scholar
• Zhang J, Liu H, Hou L, et al. Circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expression. Mol Cancer. 2017 Sep 11;16(1):151. doi: 10.1186/s12943-017-0719-3
   PubMedGoogle Scholar
• Xu C, Zhou G, Sun Z, et al. miR-148a-3p inhibits the proliferation and migration of bladder cancer via regulating the expression of ROCK-1. PeerJ. 2022;10:e12724. doi: 10.7717/peerj.12724
   PubMed Web of Science ®Google Scholar
• Song M, Liu J, Zheng X, et al. MiR-148a-3p targets CEMIP to suppress the genesis of gastric cancer cells. Biochem Biophys Res Commun. 2021 Oct 20;575:42–49. doi: 10.1016/j.bbrc.2021.08.039
   PubMed Web of Science ®Google Scholar
• Ling S, Li J, Shan Q, et al. USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway. Mol Oncol. 2017 Jun;11(6):682–695. doi: 10.1002/1878-0261.12067
   PubMed Web of Science ®Google Scholar
• Liu H, Liu N, Zhao Y, et al. Oncogenic USP22 supports gastric cancer growth and metastasis by activating c-Myc/NAMPT/SIRT1-dependent FOXO1 and YAP signaling. Aging. 2019 Nov 4;11(21):9643–9660. doi: 10.18632/aging.102410
   PubMedGoogle Scholar
• Rothzerg E, Ho XD, Xu J, et al. Upregulation of 15 antisense Long non-coding RNAs in osteosarcoma. Genes. 2021 Jul 26;12(8):1132. doi: 10.3390/genes12081132
   PubMed Web of Science ®Google Scholar
• Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017 Oct 12;36(41):5661–5667. doi: 10.1038/onc.2017.184
   PubMed Web of Science ®Google Scholar
• Bai J, Yao B, Wang L, et al. lncRNA A1BG-AS1 suppresses proliferation and invasion of hepatocellular carcinoma cells by targeting miR-216a-5p. J Cell Biochem. 2019 Jun;120(6):10310–10322. doi: 10.1002/jcb.28315
   PubMed Web of Science ®Google Scholar
• Wang Y, Hu Y, Guo J, et al. miR-148a-3p suppresses the proliferation and invasion of esophageal cancer by targeting DNMT1. Genet Test Mol Biomarkers. 2019 Feb;23(2):98–104. doi: 10.1089/gtmb.2018.0285
   PubMed Web of Science ®Google Scholar
• Li H, Hong J, Wijayakulathilaka W. RETRACTED ARTICLE: long non-coding RNA SNHG4 promotes cervical cancer progression through regulating c-met via targeting miR-148a-3p. Cell Cycle. 2019 Dec;18(23):3313–3324. doi: 10.1080/15384101.2019.1674071
   PubMed Web of Science ®Google Scholar
• Chen S, Liu Y, Zhou H. Advances in the development ubiquitin-specific peptidase (USP) inhibitors. Int J Mol Sci. 2021 Apr 27;22(9):4546. doi: 10.3390/ijms22094546
   PubMed Web of Science ®Google Scholar
• Guo J, Zhao J, Fu W, et al. Immune evasion and drug resistance mediated by USP22 in cancer: novel targets and mechanisms. Front Immunol. 2022;13:918314. doi: 10.3389/fimmu.2022.918314
   PubMed Web of Science ®Google Scholar
• Ao N, Liu Y, Feng H, et al. Ubiquitin-specific peptidase USP22 negatively regulates the STAT signaling pathway by deubiquitinating SIRT1. Cell Physiol Biochem. 2014;33(6):1863–1875. doi: 10.1159/000362964
   PubMedGoogle Scholar
• Wang Z, Chen W. Emerging roles of SIRT1 in cancer drug resistance. Genes Cancer. 2013 Mar;4(3–4):82–90. doi: 10.1177/1947601912473826
   PubMedGoogle Scholar
• Zainabadi K. Drugs targeting SIRT1, a new generation of therapeutics for osteoporosis and other bone related disorders? Pharmacol Res. 2019 May;143:97–105. doi: 10.1016/j.phrs.2019.03.007
   PubMed Web of Science ®Google Scholar
• Liu Y, Feng W, Dai Y, et al. Single-cell transcriptomics reveals the complexity of the tumor microenvironment of treatment-naive osteosarcoma. Front Oncol. 2021;11:709210. doi: 10.3389/fonc.2021.709210
   PubMed Web of Science ®Google Scholar